Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (101)	4/30/2019 4:36:32 PM
From: DewDiligence_on_SI	Respond to of 138

I don't think I learned anything of consequence from reading those tweets.

To: tuck who wrote (101)	5/3/2019 2:46:02 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 138

I am in Croatia, slow respond. Longer trial is must, surrogate/biopsy (sampling and errors) is just one measure that my warrant FDA blessing but market (MDs) will have their own opinions (PCSK9 is good experience/example). My concern is blind nature for placebo and will died/life stile last long to alter/mask any drug benefit??? For that reason, I am interested in other metabolic(important) parameters not only liver fibrosis. THR-agonist, for that reasons, are good candidates....will there be real medical benefit....only progress to cirrhosis is true measure, IMO.